Literature DB >> 12832227

Neurotrophic factors for the investigation and treatment of movement disorders.

Justo Garcia De Yébenes1, Marina Sánchez, Maria Angeles Mena.   

Abstract

Neurotrophic factors (NFs) are proteins that enhance neuronal survival, differentiation, neurotransmitter function and resistance to neurotoxins and lesions. For these reasons the NFs are considered as a new potential therapeutic tool for the treatment of neurodegenerative disorders, a group of diseases that produce the most important cause for disability in the Western world. Some NFs prevent or even reverse the behavioral, biochemical, pharmacological and histological abnormalities observed in several in vitro and in vivo models of neurodegenerative disorders, namely Parkinson's disease. Several NFs have been investigated in primate models of neurological disorders and some of them have been used for patients with these diseases. The results so far obtained in humans have been disappointing for several reasons, including technical problems for delivery, unbearable side effects or lack of efficacy. Future approaches for the use of NFs in humans should include the following: (1) Investigation of the putative compounds in animal models more related to the pathophysiology of each disease, such as in genetic models of neurodegenerative diseases; (2) New methods of delivery including genetic engineering by viral vectors and administration through implantable devices; (3) More precise methods of continuous response evaluation, including the novel neuroimaging techniques; (4) Investigation of the effects of behavioral stimulation and conventional pharmacotherapy on the metabolism of NFs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12832227     DOI: 10.1007/bf03033377

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  177 in total

1.  Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal.

Authors:  S COHEN
Journal:  J Biol Chem       Date:  1962-05       Impact factor: 5.157

2.  Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine.

Authors:  E Grünblatt; S Mandel; G Maor; M B Youdim
Journal:  J Neurochem       Date:  2001-07       Impact factor: 5.372

3.  Alteration of cellular adhesion by nerve growth factor.

Authors:  D Schubert; C Whitlock
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

4.  Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates.

Authors:  E F Espejo; R J Montoro; J A Armengol; J López-Barneo
Journal:  Neuron       Date:  1998-02       Impact factor: 17.173

5.  Identification and characterization of a novel member of the nerve growth factor/brain-derived neurotrophic factor family.

Authors:  A Hohn; J Leibrock; K Bailey; Y A Barde
Journal:  Nature       Date:  1990-03-22       Impact factor: 49.962

Review 6.  Functions of brain-derived neurotrophic factor, insulin-like growth factor-I and basic fibroblast growth factor in the development and maintenance of dopaminergic neurons.

Authors:  K D Beck
Journal:  Prog Neurobiol       Date:  1994-12       Impact factor: 11.685

7.  Parallel induction of the formation of dopamine and its metabolites with induction of tyrosine hydroxylase expression in foetal rat and human cerebral cortical cells by brain-derived neurotrophic factor and glial-cell derived neurotrophic factor.

Authors:  S Theofilopoulos; J Goggi; S S Riaz; E Jauniaux; G M Stern; H F Bradford
Journal:  Brain Res Dev Brain Res       Date:  2001-04-30

8.  Visualization of growth factor receptor sites in rat forebrain.

Authors:  R Quirion; D Araujo; N P Nair; J G Chabot
Journal:  Synapse       Date:  1988       Impact factor: 2.562

9.  Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons--I. Effects in vitro.

Authors:  E Mayer; S B Dunnett; R Pellitteri; J W Fawcett
Journal:  Neuroscience       Date:  1993-09       Impact factor: 3.590

10.  Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3.

Authors:  B Knüsel; J W Winslow; A Rosenthal; L E Burton; D P Seid; K Nikolics; F Hefti
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

View more
  2 in total

1.  Social differences associated with the use of psychotropic drugs among men and women aged 65 to 74 years living in the community: the International Mobility in Aging Study (IMIAS).

Authors:  Gustave Noufou Nana; Boukaré Doulougou; Fernando Gomez; Alban Ylli; Jack Guralnik; Maria Victoria Zunzunegui
Journal:  BMC Geriatr       Date:  2015-07-20       Impact factor: 3.921

Review 2.  Brain sites of movement disorder: genetic and environmental agents in neurodevelopmental perturbations.

Authors:  T Palomo; R J Beninger; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.